

Special Issue

Significance of CAR T-Cell Therapy in Aggressive B-Cell Lymphoma Treatment

Message from the Guest Editor

Recently FDA-approved, patients who have relapsed non-Hodgkin and Hodgkin lymphomas can be treated with anti-CD19 CAR-T therapy. Extensive basic and translational research provides insights into the efficacy, toxicity, and potential resistance mechanisms of these therapies. While CAR-T therapy offers significant clinical benefits, efforts to enhance its efficacy and reduce its toxicity are ongoing. This Special Issue aims to publish research articles and reviews on the following topics:

- Current updates on the efficacy and immune-related adverse events of the six CAR-T therapies that have been FDA-approved for treating refractory and relapsed lymphomas, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, and primary/secondary central nervous system lymphoma.
- Preclinical or clinical trial studies on combination therapies with CAR-T cells.

Novel target discovery and multidimensional omics data analyses of the lymphoma microenvironment and CAR-T persistence in aggressive B-cell lymphoma.

Guest Editor

Dr. Wing Keung Chan

Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH 43210, United States

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/217556

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)